

## > PROJECT PROFILE FOR IN-LICENSING

- > **TYPE OF MOLECULE:** Small molecule (new chemical entity). Occasionally, peptide could be also considered.
  
- > **DEVELOPMENT STAGE:** Late preclinical or early clinical Phase I.
  - Lead optimization finished and final candidate selected.
  - Validated target in animal models or in humans.
  - Positive preclinical results in well established animal models.
  - Preclinical results under GLP conditions is a plus.
  
- > **INTELLECTUAL PROPERTY (IP):** Strong patent protection
  
- > **INDICATIONS:** Acne Vulgaris, Allergic rhinitis, Asthma, Atopic dermatitis, Back Pain, Contact dermatitis, COPD, Crohn's Disease, Neuropathic Pain, Osteoarthritis, Osteoporosis, Psoriasis, Rheumatoid Arthritis, Seborrheic dermatitis, Systemic Lupus Erythematosus, Ulcerative Colitis.
  
- > **ROUTE OF DELIVERY:**
  - Preferably oral.
  - Topical.
  - Indications that require medical devices will need an economic-business assessment.
  
- > **LICENSING TERRITORY RIGHTS:** Worldwide
  
- > **MARKET POTENTIAL:** > €500 millions worldwide peak sales

### Contacts

For further information on Palau Pharma and its products, please visit

[www.palaupharma.com](http://www.palaupharma.com)

or contact:

Heidi Sisniega  
Head of Business Development & Licensing  
P: +34.93.863.0483  
E: [hsisniega@palaupharma.com](mailto:hsisniega@palaupharma.com)

Palau Pharma, S.A.  
Pol. Ind. Riera de Caldes  
Av. Camí Reial, 51-57  
08184 Palau-solità i Plegamans  
(Barcelona), Spain